In the metastatic prostate adenocarcinoma cell line (LNCaP) and the primary prostate cancer cell line (22Rv1), treatment with cadmium induced a significant increase in p53 levels, highlighting the capacity of cadmium to induce p53-dependent apoptosis in tumor cells and inhibit cell proliferation [55]. Here, TP53 is linked to prostate carcinoma.